Table 3

Two-Year Outcome Events in Patients With Normal Versus Abnormal MPS

AllPatients With Normal MPS
(n = 306)
Patients With Abnormal MPS
(n = 82)
HR/OR (95% CI)p Value
Patients with MACE17 (4.4)9 (2.9)8 (9.8)3.44 (1.32–8.95)0.011
Cardiac death4 (1.0)2 (0.7)2 (2.4)3.77 (0.53–26.77)0.184
Myocardial infarction6 (1.6)3 (1.0)3 (3.7)3.77 (0.76–18.69)0.104
Revascularization12 (3.1)6 (2.0)6 (7.3)3.90 (1.25–12.16)0.019
Scintigraphic ischemia or new scar34 (9.5)9 (3.2)25 (34.2)15.91 (7.24–38.03)<0.001
Patients with “overt or silent CAD progression”39 (10.9)13 (4.6)26 (35.6)11.53 (5.63–24.70)<0.001

Values are n (%).

CAD = coronary artery disease; CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac events; MPS = myocardial perfusion single-photon emission computed tomography; OR = odds ratio.

  • p values from Cox proportional-hazards survival model (HR and 95% CI) except for scintigraphic ischemia or new scar and “overt or silent CAD progression” (OR and 95% CI from generalized linear model).

  • n = 284 and n = 73 for patients with normal and abnormal MPS, respectively.